Phase 2, multicenter, randomized, double blind, placebo controlled study of combination therapy for safety and efficacy in subjects with uncomplicated obesity

Trial Profile

Phase 2, multicenter, randomized, double blind, placebo controlled study of combination therapy for safety and efficacy in subjects with uncomplicated obesity

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2010

At a glance

  • Drugs Bupropion; Naltrexone
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2010 Naltrexone/bupropion has received a positive recommendation from the FDA Advisory Committee for the treatment of obesity, as reported in an Orexigen Therapeutics and Takeda Pharmaceutical Company media release
    • 01 Dec 2009 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 01 Dec 2009 Primary endpoint 'Bodyweight reduction' has been met according to results published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top